Top Biopharma Trends to Watch in 2025
2025 is shaping up to be a promising year for the biopharma industry, according to C-suite executives from pharmaceutical, biotechnology, and life sciences companies. Based on a survey conducted by the Deloitte Center for Health Solutions, 75% of these executives are optimistic about the year ahead, anticipating revenue growth and the continuation of scientific and technological innovation.
Analysts predict a resurgence in merger and acquisition (M&A) activity within the life sciences sector after a slowdown in 2024. This trend is expected to span across biotech, pharmaceuticals, and medtech, including diagnostics and medical devices.
In interviews with experts and industry stakeholders, GEN has uncovered seven biopharma trends to watch in 2025. One of these trends is the continued growth of artificial intelligence (AI) beyond drug discovery algorithms. Executives are planning to expand their investments in AI technology across their value chains to improve business operations and efficiency.
Leading AI-based drug developers like Recursion and Insilico Medicine are making significant strides in the field. Recursion recently partnered with Exscientia, while Insilico Medicine has expanded its pipeline to 31 programs, with 10 in clinical phases.
The use of AI in biopharma is expected to drive growth for companies utilizing this technology. Some firms are developing their AI platforms, while others are choosing to partner with established AI companies to enhance their internal programs.
The cancer vaccine space will also see significant progress in 2025, with late-stage data gathering from leading developers like Moderna and Merck. These companies have launched Phase III trials for their individualized neoantigen therapies, showing promise in treating non-small cell lung cancer and other types of cancer.
Overall, 2025 holds promising prospects for the biopharma industry, with advancements in AI technology and cancer vaccine development expected to drive growth and innovation in the coming year.
